New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2012
09:00 EDTKALU, DG, KFT, CHK, AZN, CERN, PPG, IDIX, CMP, ARII, MDT, EME, BSYBY, HMSY, CPNOn The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: American Railcar (ARII) upgraded to Neutral from Sell at UBS...AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies and to Neutral from Underweight at JPMorgan...Calpine (CPN) upgraded to Buy from Hold at Jefferies...Chesapeake (CHK) upgraded to Outperform from Market Perform at BMO Capital...Compass Minerals (CMP) upgraded to Buy from Hold at KeyBanc...HMS Holdings (HMSY) upgraded to Buy from Hold at Jefferies...Idenix (IDIX) upgraded to Market Perform from Underperform at JMP Securities...Kraft Foods (KFT) upgraded to Overweight from Neutral at JPMorgan...British Sky Broadcasting (BSYBY) upgraded to Buy from Neutral at Citigroup...PPG Industries (PPG) upgraded to Outperform from Neutral at Credit Suisse...Dollar General (DG) upgraded to Strong Buy from Outperform at Raymond James...EMCOR Group (EME) upgraded to Buy from Hold at Stifel Nicolaus...Cerner (CERN) upgraded to Outperform from Market Perform at Raymond James...Kaiser Aluminum (KALU) upgraded to Buy from Hold at Dahlman Rose...Medtronic (MDT) upgraded to Buy from Neutral at Lazard Capital.
News For ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 19, 2015
10:02 EDTCERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTCHKOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTPPGPPG Industries completes $40M expansion at Brazil facility
PPG Industries held a ceremony to mark the completion of a $40M, 65,000-square-foot plant for on-site resin production at its Sumaré, São Paulo, Brazil, coatings manufacturing facility. Resin produced at the facility will be used to manufacture PPG’s electrocoat products to meet demand from automotive original equipment manufacturers and industrial coatings customers in the region.
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information
08:24 EDTCHKChesapeake downgraded at Sterne Agee
Subscribe for More Information
06:20 EDTCHKChesapeake downgraded to Underperform from Neutral at Sterne Agee
March 18, 2015
17:19 EDTHMSYHMS Holdings initiated with an Outperform at RW Baird
Subscribe for More Information
16:06 EDTCERNCerner upgraded to Outperform from Neutral at RW Baird
Subscribe for More Information
09:33 EDTCERNCerner selected by Washington hospitals to update health record systems
The State of Washington Department of Social and Health Services has selected health IT supplier Cerner to modernize integrated revenue cycle and electronic health records in multiple state facilities to prepare for ICD-10 compliance. The agreement will digitize DSHS' paper health records. Cerner will implement Millennium PowerChart and the revenue cycle suite of solutions at three accredited psychiatric hospitals, including Western State Hospital, Eastern State Hospital and Child Studies and Treatment Center. Cerner will replace the billing functionality supported by the Residential Programs System, as well as the central pharmacy system. DSHS' system will be hosted at Cerner's Kansas City data center.
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:58 EDTDGGIC Private Limited reports 5.02% passive stake in Dollar General
Subscribe for More Information
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
10:00 EDTCHKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:13 EDTCHKChesapeake downgraded to Sell from Neutral at Global Hunter
March 16, 2015
13:16 EDTMDTAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
07:30 EDTMDT, AZNAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use